Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

The US saw several new and expanded FDA indications this year. The top 5 most-read FDA approvals on AJMC.com included 4 novel therapies and 1 expanded indication, reflecting the growing number of ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Jascayd becomes the first and only preferential ...

Results from the FIBRONEER-ILD trial showed nerandomilast significantly slowed lung function decline in patients with PPF compared with placebo. The Food and Drug Administration (FDA) has expanded the ...

Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This groundbreaking medication goes beyond merely alleviating ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. 1, 2 Affecting up to 100,000 people in the U.S. and up to 5.6 ...

/PRNewswire/ -- Boehringer Ingelheim's JASCAYD ® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in ...

Some cheddar cheese products branded as Charlevoix Cheese Company Farm have been recalled due to potential Listeria contamination. Flu activity is high or very high in 17 U.S. jurisdictions, with two ...

* In FIBRONEERTM-ILD, adverse events led to permanent discontinuation of the trial regimen in 10.0% of the JASCAYD 18 mg group, 8.1% in the JASCAYD 9 mg group, and 10.2% in the placebo group. 6 ...